Biblio Discovery — Demo Discovery Service

292 results

Showing 1–20 · 0.54 seconds · RSS

Journal

Oncology and Therapy

Scopus

ISSN 2366-1070 · Adis, Springer Healthcare · 292 articles in the index

  1. Journal Article

    A Qualitative Study of Patient and Caregiver Perspectives on Locally Advanced Head and Neck Cancer in the United States

    Esther Yu; Veronica Ashton; OluYemisi Falope et al.

    Oncology and Therapy, Vol. 14 No. 3 · 2026 · English · DOAJ Scopus

    Abstract Introduction Locally advanced head and neck squamous cell carcinoma (LA-HNSCC) has major physical and psychosocial burdens. Although treatment challenges are well recognized, few studies have explored the full LA-HNSCC experience from first symptoms through to post-treatment recovery and…

  2. Journal Article

    Exceptional Cure of a Patient with Progressive Advanced Squamous-Cell Lung Cancer after Selenite Treatment followed by Chemotherapy: A Case Report

    Ola Brodin; Carlos Fernandez Moro; Mattias Hedman et al.

    Oncology and Therapy, Vol. 14 No. 3 · 2026 · English · DOAJ Scopus

    Abstract Intravenous (i.v.) sodium selenite has been evaluated in patients with advanced cancer, but its potential clinical and biomarker-related effects remain incompletely understood. We report a patient with advanced squamous-cell lung cancer who was treated with high-dose intravenous sodium…

  3. Journal Article

    Real-World Outcomes Among Medicare Beneficiaries Treated with Bruton Tyrosine Kinase Inhibitors for Treatment-Naïve CLL

    Daniel A. Ermann; Deborah M. Stephens; Xiaoliang Wang et al.

    Oncology and Therapy, Vol. 14 No. 3 · 2026 · English · DOAJ Scopus

    Abstract Introduction There is a dearth of head-to-head studies comparing covalent Bruton tyrosine kinase (cBTK) inhibitors in adults with chronic lymphocytic leukemia (CLL). Real-world evidence may complement clinical trial data by assessing relative effectiveness in routine practice. This…

  4. Journal Article

    Ceralasertib Plus Durvalumab in Chinese Patients with Advanced Solid Tumors: A Nonrandomized Clinical Trial

    Yuping Sun; Jia Zhong; Huiwen Sun et al.

    Oncology and Therapy, Vol. 14 No. 3 · 2026 · English · DOAJ Scopus

    Abstract Introduction This phase I, multicenter, nonrandomized open-label study is the first study to investigate the safety, pharmacokinetics, and antitumor activity of ceralasertib, an oral ATR kinase inhibitor, in combination with durvalumab in Chinese patients with advanced solid tumors who are…

  5. Journal Article

    Beyond the BCG Paradox: Biological Rationale and Clinical Evidence for Combining Intravesical BCG with Immune Checkpoint Inhibitors in High-Risk Non-muscle-Invasive Bladder Cancer

    Michele Musone; Biagio Barone; Stefano Chianese et al.

    Oncology and Therapy, Vol. 14 No. 3 · 2026 · English · DOAJ Scopus

    Abstract Bladder cancer (BC) is the most common malignancy of the urinary tract, with more than 75% of cases diagnosed as non-muscle-invasive bladder cancer (NMIBC). Intravesical Bacillus Calmette–Guérin (BCG) remains the gold standard adjuvant treatment for high-risk NMIBC owing to its ability to…

  6. Journal Article

    Podcast on the Emerging Role of PD-(L)1/VEGF Bispecific Antibodies in the Evolving Advanced Renal Cell Carcinoma Treatment Landscape

    Brian I. Rini; Benjamin Garmezy

    Oncology and Therapy, Vol. 14 No. 3 · 2026 · English · DOAJ Scopus

    Abstract Combinations of an immune checkpoint inhibitor (ICI) + anti-programmed cell death 1 protein (PD-1) or anti-programmed cell death ligand 1 (PD-L1) or an ICI + tyrosine kinase inhibitor (TKI; anti-vascular endothelial growth factor [VEGF]) are the current standard first-line treatments for…

  7. Journal Article

    Evaluation of Drug–Drug Interactions Using Drug-PIN® in Patients Receiving Avelumab Maintenance for Advanced Urothelial Carcinoma: Evidence from the MALVA Study (Meet-URO 25)

    Giandomenico Roviello; Mattia Alberto Di Civita; Daniele Santini et al.

    Oncology and Therapy, Vol. 14 No. 3 · 2026 · English · DOAJ Scopus

    Abstract Introduction Polypharmacy is common in patients with advanced urothelial carcinoma (UC) receiving avelumab maintenance therapy, raising concerns about potential drug–drug interactions (DDIs). Methods We retrospectively analyzed patients enrolled in the multicenter MALVA study treated with…

  8. Journal Article

    Clinicians’ Perspectives on the Impact of Different Attributes of Androgen Receptor Pathway Inhibitors on Prostate Cancer Treatment Preferences and Compliance in Mexico

    Mario Escobar Gómez; Ana Maria Rodríguez-Leboeuf; Selene Camargo-Correa et al.

    Oncology and Therapy, Vol. 14 No. 3 · 2026 · English · DOAJ Scopus

    Abstract Introduction Androgen receptor pathway inhibitors (ARPIs) are a critical prostate cancer (PC) treatment option. Previous research has suggested that the physical attributes of ARPI medications (e.g., pill formulation, pill shape, pill size, dosing) may influence patients’ treatment…

  9. Journal Article

    Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC): An Aggressive Disease Course and Limitations for Personalized Oncology

    Celine Oanæs; Herish Garresori; Dordi Lea et al.

    Oncology and Therapy, Vol. 14 No. 3 · 2026 · English · DOAJ Scopus

    Abstract Neuroendocrine carcinoma (NEC) is a rare, aggressive malignancy with limited treatment options and poor prognosis. We report a male patient diagnosed with a gastroenteropancreatic (GEP)-NEC with synchronous liver metastasis at the time of surgery who underwent a radical resection attempt…

  10. Journal Article

    IMMPACT-MM: Insights into Multiple Myeloma Patient Outcomes following Early-Line Cilta-cel Treatment

    Sridevi Rajeeve; Saurabh P. Nagar; Sabyasachi Ghosh et al.

    Oncology and Therapy, Vol. 14 No. 3 · 2026 · English · DOAJ Scopus

    Abstract Introduction Ciltacabtagene autoleucel (cilta-cel) has demonstrated deep and durable responses in patients with relapsed/refractory multiple myeloma (RRMM), supporting the goal of sustained minimal residual disease (MRD) negativity as a marker for potential functional cure, characterized…

  11. Journal Article

    A Comprehensive Mapping of Real-World Studies and Data Sources for Oncology in China: Insights into Landscape, Challenges, and Future Direction

    Yaqi Jia; Yanbing Li; Siyan Zhan et al.

    Oncology and Therapy, Vol. 14 No. 3 · 2026 · English · DOAJ Scopus

    Abstract Introduction Cancer remains a major public health concern in China, with approximately 2.57 million cancer-related deaths reported in 2022. Real-world studies (RWS), which leverage high-quality real-world data (RWD), can generate robust real-world evidence (RWE) to enhance clinical…

  12. Journal Article

    Abemaciclib in HR+, HER2− Breast Cancer: A Narrative Review of the Clinical Evidence

    Miguel Martin; Alexandru Rosca; Alexandra Searles Vitko et al.

    Oncology and Therapy, Vol. 14 No. 3 · 2026 · English · DOAJ Scopus

    Abstract Hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2–) breast cancer comprises approximately 70% of all breast cancer cases. In early-stage breast cancer, adjuvant endocrine therapy (ET) reduces recurrence and mortality, while in advanced/metastatic breast cancer…

  13. Journal Article

    Patient-Reported Outcome Instruments in Non-Muscle-Invasive Bladder Cancer (NMIBC): A Systematic Review

    Ingolf Griebsch; Sunil Shrestha; Carolyn C. Gotay et al.

    Oncology and Therapy, Vol. 14 No. 3 · 2026 · English · DOAJ Scopus

    Abstract Introduction Non-muscle-invasive bladder cancer (NMIBC) is a chronic and recurrent condition requiring repeated intravesical treatments and lifelong surveillance, imposing a substantial burden on patients. Patient-reported outcomes (PROs) are increasingly required by regulatory bodies and…

  14. Journal Article

    Machine Learning-Guided Survival Prediction and Treatment Sequencing in Advanced Soft Tissue Sarcoma Beyond Second-Line Therapy: A Retrospective Cohort Study

    Michael Hoberger; Dorit Di Gioia; Romy L. Zuber et al.

    Oncology and Therapy, Vol. 14 No. 3 · 2026 · English · DOAJ Scopus

    Abstract Introduction Evidence guiding the optimal sequencing of later-line systemic therapy in advanced soft tissue sarcoma (STS) remains limited. The aim of this study was to identify prognostic factors for overall survival (OS) beyond second-line treatment and to explore therapy sequencing in…

  15. Journal Article

    Real-World Actionability Analysis of Comprehensive Genomic Profiling Versus Single/Small-Gene Panels

    Paul Spin; Bela Bapat; Chad Moretz et al.

    Oncology and Therapy, Vol. 14 No. 3 · 2026 · English · DOAJ Scopus

    Abstract Introduction Comprehensive genomic profiling (CGP) enables identification of patients eligible for targeted treatments, making it essential in the management of advanced cancer. This retrospective real-world study compared actionable mutations in CGP-tested patients with…

  16. Journal Article

    A Comprehensive Review of the Role of Zanubrutinib for Patients with Chronic Lymphocytic Leukemia

    Paolo Ghia; Jennifer R. Brown; Mazyar Shadman et al.

    Oncology and Therapy, Vol. 14 No. 2 · 2026 · English · DOAJ Scopus

    Abstract The approval of ibrutinib over a decade ago introduced Bruton tyrosine kinase (BTK) inhibition as a foundational, chemotherapy-free treatment approach for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). A continuous single-agent BTK inhibitor (BTKi) or a…

  17. Journal Article

    Evolving Concepts in Salivary Duct Carcinoma: A Narrative Review

    Marvin C. Masalunga; Patrick J. Bradley; Carla van Herpen et al.

    Oncology and Therapy, Vol. 14 No. 2 · 2026 · English · DOAJ Scopus

    Abstract Salivary duct carcinoma (SDC) is an aggressive neoplasm that typically involves the major salivary glands. This rapidly growing tumor is known to recur and metastasize to the neck nodes and to distant sites. Given its poor prognosis, researchers have focused on identifying factors and…

  18. Journal Article

    Association of Variants in Candidate Pharmacogenes with Response to Mercaptopurine and Methotrexate in Pediatric Acute Lymphoblastic Leukemia: A Single-Center Experience from Croatia

    Isidora Curic; Nikola Kotur; Bojan Ristivojevic et al.

    Oncology and Therapy, Vol. 14 No. 2 · 2026 · English · DOAJ Scopus

    Abstract Introduction Interindividual variability in the efficacy and toxicity of 6-mercaptopurine (6-MP) and methotrexate (MTX) drugs remains a major challenge in the treatment of pediatric acute lymphoblastic leukemia (ALL). Germline variation in pharmacogenes involved in drug metabolism…